Physician profile
Daniel E Roth
NPI 1699814350
$3,111.81
in general payments reported to CMS, 2019-2025
27 companies · $404 in 2025
The $404 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,232 · 2020: $304 · 2021: $485 · 2023: $151 · 2024: $536 · 2025: $404.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073 · Education: $17.36.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,073.41 |
| Education | $17.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $402.04 | 2019-2025 | Airsupra, Breztri |
| Novo Nordisk INC | $361.00 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $355.82 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Pfizer INC. | $350.00 | 2019-2025 | |
| Glaxosmithkline, LLC. | $334.24 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $268.89 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.58 | 2019-2025 | Jardiance |
| Abbvie INC. | $172.93 | 2019-2025 | Ubrelvy |
| Merck Sharp & Dohme LLC | $90.36 | 2019 | |
| Gilead Sciences, INC. | $60.91 | 2019 | |
| Ivantis, INC | $59.99 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $56.16 | 2019 | |
| Sanofi Pasteur INC. | $48.18 | 2019-2025 | |
| Mallinckrodt Hospital Products INC. | $44.78 | 2020 | |
| Daiichi Sankyo INC. | $40.33 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $38.20 | 2019-2021 | |
| Insulet Corporation | $25.80 | 2019 | |
| Allergan, INC. | $24.44 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $24.09 | 2024 | Eliquis |
| Astellas Pharma US INC | $23.47 | 2019 | |
| Mannkind Corporation | $21.17 | 2019 | |
| Celgene Corporation | $19.02 | 2019 | |
| Medtronic, INC. | $18.41 | 2021 | |
| Viiv Healthcare Company | $17.36 | 2023 | Apretude |
| Endo Pharmaceuticals INC. | $17.30 | 2019 | |
| Janssen Pharmaceuticals, INC | $16.70 | 2019 | |
| Circassia INC. | $16.64 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.